ACM
ACT Capital Management Portfolio holdings
AUM
$72.5M
This Quarter Return
+6.71%
1 Year Return
-33.17%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$72.5M
AUM Growth
+$72.5M
(+1.3%)
Cap. Flow
+$555K
Cap. Flow
% of AUM
0.77%
Top 10 Holdings %
Top 10 Hldgs %
68.94%
Holding
88
New
10
Increased
5
Reduced
18
Closed
17
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$3.26M |
| 2 |
Exxon Mobil
XOM
|
$2.16M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$1.47M |
| 4 |
Vital Energy
VTLE
|
$1.33M |
| 5 |
Diamondback Energy
FANG
|
$783K |
Top Sells
| 1 |
IDEAYA Biosciences
IDYA
|
$2.39M |
| 2 |
Arcturus Therapeutics
ARCT
|
$1.57M |
| 3 |
Lantheus
LNTH
|
$852K |
| 4 |
Arrowhead Research
ARWR
|
$810K |
| 5 |
CF Industries
CF
|
$772K |
Sector Composition
| 1 | Healthcare | 60.86% |
| 2 | Energy | 29.19% |
| 3 | Technology | 7.52% |
| 4 | Communication Services | 1.77% |
| 5 | Industrials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
STAAR Surgical
STAA
$1.36B
| $15.7M | 21.69% | 222,800 -6,100 | -3% | -$430K |
|
|
2
Exxon Mobil
XOM
$487B
| $7.12M | 9.83% | 81,600 +24,700 | +43% | +$2.16M |
|
3
Devon Energy
DVN
$22.9B
| $4.96M | 6.85% | 82,500 | – | – |
|
4
Krystal Biotech
KRYS
$4.27B
| $4.06M | 5.61% | 58,300 -700 | -1% | -$48.8K |
|
|
5
Arrowhead Research
ARWR
$3.05B
| $3.65M | 5.04% | 110,500 -24,500 | -18% | -$810K |
|
|
6
Axsome Therapeutics
AXSM
$6.05B
| $3.26M | 4.5% | +73,000 | New | +$3.26M |
|
7
Chevron
CVX
$324B
| $3.23M | 4.46% | 22,500 +3,000 | +15% | +$431K |
|
8
Adtran
ADTN
$751M
| $2.94M | 4.05% | 150,000 | – | – |
|
9
enVVeno Medical
NVNO
$15.4M
| $2.52M | 3.48% | 401,200 | – | – |
|
10
Clearside Biomedical
CLSD
$28.9M
| $2.48M | 3.43% | 2,197,480 -90,720 | -4% | -$103K |
|
|
11
Vital Energy
VTLE
$690M
| $2.13M | 2.94% | 33,900 +21,100 | +165% | +$1.33M |
|
|
12
Arcturus Therapeutics
ARCT
$462M
| $1.78M | 2.46% | 120,400 -106,200 | -47% | -$1.57M |
|
|
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.77M | 2.44% | 235,000 -15,000 | -6% | -$113K |
|
|
VRNA
14
Verona Pharma
VRNA
$9.16B
| $1.47M | 2.02% | +143,500 | New | +$1.47M |
|
15
Energy Transfer Partners
ET
$60.8B
| $1.41M | 1.95% | 127,800 | – | – |
|
|
16
Diamondback Energy
FANG
$43.1B
| $1.27M | 1.75% | 10,500 +6,500 | +163% | +$783K |
|
|
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.08M | 1.49% | 60,000 -5,000 | -8% | -$89.8K |
|
18
INmune Bio
INMB
$54M
| $937K | 1.29% | 151,100 -9,400 | -6% | -$58.3K |
|
19
Inhibikase Therapeutics
IKT
$134M
| $853K | 1.18% | 937,500 | – | – |
|
20
Roku
ROKU
$14.2B
| $761K | 1.05% | 13,500 +7,900 | +141% | +$445K |
|
|
AFMD
21
DELISTED
Affimed
AFMD
| $636K | 0.88% | 308,800 | – | – |
|
22
Cambium Networks
CMBM
$21.5M
| $582K | 0.8% | +34,400 | New | +$582K |
|
23
Transmedics
TMDX
$3.92B
| $522K | 0.72% | +12,500 | New | +$522K |
|
24
Stratasys
SSYS
$906M
| $504K | 0.7% | 35,000 -15,000 | -30% | -$216K |
|
25
Champions Oncology
CSBR
$93.8M
| $469K | 0.65% | 62,500 | – | – |
|